NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Omeros Corp. OMER
17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.4M
$-116.2M
In brief
What this company does
Written from the business description in OMEROS CORP's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.
Growth
—
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2020 · Revenue 73.8 · Net income -138.1
Compound annual growth
Revenue compounded at +40.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2020 · Operating -212.6% · Net -187.0%
ROE
FY2023 · ROE -388.2%
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | · | · | · | · | · | · | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.2 | −0.1 | 0.0 | 0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.05 | −2.70 | −1.88 | 0.76 | 3.12 | −2.41 | −1.71 | −2.61 | −1.17 | −1.65 | −2.00 | −2.22 | −1.39 | −1.59 | −1.29 | −1.37 | −2.92 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | −388.2 | 86.6 | · | · | · | · | · | · | · | · | · | · | −382.8 | −92.0 | −48.9 |
| Shares out B | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 22 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inWashington
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009